Entrez PubMed The neuronal ceroid lipofuscinosis CLN8 membrane protein is a resident of the endoplasmic reticulum. Lonka L, Kyttala A, Ranta S, Jalanko A, Lehesjoki AE. http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=1
CERF NEWS Jan 2000 neuronal ceroid lipofuscinosis (NCL) is a hereditary, progressive, disease in dogs and humans, which commonly leads to blindness and other neurologic http://www.vmdb.org/jan00.html
Extractions: There have been many questions recently regarding the comparison of Optigen and CERF's information with regards to PRA in Labs. It is important that one does not try to simply do a direct comparison of these two sets of numbers. Due to many factors these two sets of statistics will not match. For more information about this please see the article on OptiGen's web site at www.optigen.com Neuronal Ceroid Lipofuscinosis (NCL) is a hereditary, progressive, disease in dogs and humans, which commonly leads to blindness and other neurologic problems and can lead to premature death. It is a lipid storage disease, meaning that affected individuals have an abnormal ability to store fat-associate pigments (lipopigments) in their bodies. Many biochemical defects have been implicated in these lipid storage diseases. NCL causes degeneration of the retina and usually affects the central nervous system (the brain) as well. NCL has been described in several breeds including the English setter, dalmatian, Border collie, Tibetan terrier, Polish Owczarek Nizinni (PON), and the miniature schnauzer.1 The hereditary mechanism by which this disease is transferred has been determined in only the English setter breed. In that breed it is inherited as an autosomal recessive trait.2
Santavuori Disease,CLN1,INCL,Infantile Neuronal Ceroid Santavuori Disease,CLN1,INCL,Infantile neuronal ceroid lipofuscinosis,neuronal ceroid lipofuscinosis Type 1,Infantile Type neuronal ceroid lipofuscinosis http://www.icomm.ca/geneinfo/santavori.htm
Kufs Disease Generalized Lipofuscinosis; neuronal ceroid lipofuscinosis, Adult Type of disorders (neuronal ceroid lipofuscinoses NCL) that are differentiated http://my.webmd.com/hw/raising_a_family/nord349.asp
Extractions: Kufs Disease is characterized by neurologic symptoms that may mimic mental illness, movement malfunction, and problems with sight. Kufs Disease is linked to excess accumulations of pigments (lipofuscins) dissolved in fat tissues that are found throughout the central nervous system. Kufs Disease, Batten Disease, Bielchowsky Disease, and Santavuori-Haltia Disease are different forms of the same family of disorders (neuronal ceroid lipofuscinoses [NCL]) that are differentiated by the age of onset. The various forms of this disorder are often extremely difficult to differentiate from other progressive degenerative diseases of the central nervous system.
Santavuori Disease CLN1; INCL; Infantile neuronal ceroid lipofuscinosis; neuronal ceroid lipofuscinosis Type 1; Infantile Type neuronal ceroid lipofuscinosis http://my.webmd.com/hw/health_guide_atoz/nord1090.asp
Extractions: Santavuori Disease, an extremely rare inherited disorder, belongs to a group of progressive degenerative neurometabolic diseases known as the neuronal ceroid lipofuscinoses (NCL). These diseases share certain similar symptoms and are distinguished in part by the age at which such symptoms appear. Santavuori Disease is considered the infantile form of the neuronal ceroid lipofuscinoses.
Extractions: Human and Clinical Genetics - LUMC (Centrum voor Humane en Klinische Genetica) Neuronal Ceroid Lipofuscinosis The neuronal ceroid lipofuscinoses (NCL) are worldwide the most common lysosomal storage disorders of childhood. Clinical features often include progressive visual impairment, seizures, psychomotor deterioration, dementia, and a premature death. Most NCL cases are caused by mutations in the CLN1, CLN2 and CLN3 genes, which play an essential role in lysosomal protein degradation. Our initial NCL research started in 1992 and concentrated on the genetic analysis of families suffering from juvenile NCL. These studies have resulted in the identification of the CLN3 gene and the development of reliable molecular diagnostics for juvenile NCL. The molecular diagnostics was later extended to include the other forms of NCL and transferred to our Clinical Molecular Genetics Laboratory . Currently, our research focuses on the development and use of
Extractions: Help Mitchell, W.A. and Wheeler, R.B. and Sharp, J.D. and Bate, S.L. and Gardiner, R.M. and Ranta, U.S. and Lonka, L. and Williams, R.E. and Lehesjoki, A.-E. and Mole, S.E. Turkish variant late infantile neuronal ceroid lipofuscinosis (CLN7) may be allelic to CLN8. European Journal of Paediatric Neurology Supplement A . ISSN Type: Article Status: Published Refereed: Yes Keywords: alleles, child, child preschool, chromosome mapping, DNA mutational analysis, DNA primers, family health, haplotypes, homozygote, humans, infant, *linkage (genetics), microsatellite repeats, neuronal ceroid-lipofuscinosis, *genetics (GE), research support, non-U.S. government, Turkey UCL Eprints classification: UCL Departments and Research Centres Faculty of Clinical Sciences Department of Paediatrics and Child Health Deposited on: 07 April 2005 Archive Staff Only: edit this record
Juvenile Neuronal Ceroid Lipofuscinosis - Information & News The aberrant protein that causes juvenile Batten disease, a fatal neurodegenerative disorder of childhood, also plays a key role in normal cell function, http://www.news-medical.net/?keyword=Juvenile neuronal ceroid lipofuscinosis
Extractions: (link to Data Sheet) Strain Type Standard Supply /J Repository-Cryopreserved. Please refer to the Supply Notes for further information. /J Repository-Cryopreserved. Please refer to the Supply Notes for further information. a a op /J Repository-Live. No age specifications accepted. Colony sized to produce minimal quantities (typically up to 6 mice) upon order receipt; one order per strain. Expected delivery: 1-3 months. Larger quantities or custom orders arranged upon request. (3 stocks) Back to top Back to Top Research Research Resources ... The Jackson Laboratory
NORD - National Organization For Rare Disorders, Inc. Infantile neuronal ceroid lipofuscinosis (INCL). At this time, there is no effective treatment available for this genetic disease, which is the infantile http://www.rarediseases.org/nord/research/infantile
Extractions: Read about events on Capitol Hill, funding for rare-disease research, and other topics of interest from NORD's office in Washington, DC. Research Infantile Neuronal Ceroid Lipofuscinosis (INCL) At this time, there is no effective treatment available for this genetic disease, which is the infantile form of a group of progressive, neurometabolic diseases. Doctors at the NIH currently are enrolling children between six months and two years of age for participation in a clinical study of the drug Cystagon for INCL. The study takes place at the NIH in Bethesda, Md. All study-related tests and medicines are provided free of charge. For more information about this National Institutes of Health (NIH) study, go to
Extractions: Genzyme Corporate Search Contact Us Genzyme Websites Lyso Learning All Genzyme sites About Lysosomal Storage Disorders Disease Classification Disease Management var pageTitle="Neuronal Ceroid Lipofuscinosis - Type II (Late Infantile Form)"; var teaserText = "Progressive accumulation of lipofuscins (lipopigments) in cells of the central nervous system, liver, muscle, blood vessels, skin, eyes, and lymphocytes."; Neuronal Ceroid Lipofuscinosis - Type II (Late Infantile Form) Select Another Disease Select disease Acid sphingomyel. def. Aspartylglycosaminuria Cystinosis Fabry disease Farber disease Fucosidosis type I Fucosidosis type II Galactosialidosis Gaucher type I Gaucher type II Gaucher type III GM1 gangliosidosis I GM1 gangliosidosis II GM1 gangliosidosis III Infantile sialic acid Krabbé disease Mannosidosis Metachr. leukodys. I
Neuronal Ceroid Lipofuscinosis - Type I (Infantile Form) Current page. neuronal ceroid lipofuscinosis type I. Select Another Disease Wisniewski, Krystyna E. MD, Ph.D. Neuronal Ceroid-Lipofuscinoses. http://www.lysosomallearning.com/healthcare/about/lsd_hc_abt_ncl1.asp
Extractions: Genzyme Corporate Search Contact Us Genzyme Websites Lyso Learning All Genzyme sites About Lysosomal Storage Disorders Disease Classification Disease Management var pageTitle="Neuronal Ceroid Lipofuscinosis - Type I (Infantile Form)"; var teaserText = "Progressive accumulation of lipofuscins (lipopigments) in cells of the central nervous system, liver, muscle, blood vessels, skin, eyes, and lymphocytes."; Neuronal Ceroid Lipofuscinosis - Type I (Infantile Form) Select Another Disease Select disease Acid sphingomyel. def. Aspartylglycosaminuria Cystinosis Fabry disease Farber disease Fucosidosis type I Fucosidosis type II Galactosialidosis Gaucher type I Gaucher type II Gaucher type III GM1 gangliosidosis I GM1 gangliosidosis II GM1 gangliosidosis III Infantile sialic acid Krabbé disease Mannosidosis Metachr. leukodys. I
Extractions: Add to Personal Archive ... PubMed Citation To the Editor: Rust and Karluk (Aug. 29 issue) discuss the case of a child with a neurodegenerative disorder who was found to have curvilinear lysosomal inclusion bodies on electron-micrographic analysis of a muscle-biopsy specimen. Late-onset infantile neuronal ceroid lipofuscinosis was diagnosed. The approach to confirming this diagnosis is puzzling. The authors mention that subsequent molecular testing for the two common mutations of failed to identify a mutation, but no enzyme testing was performed. Given that only 66 percent of patients with a clinical diagnosis of late-onset infantile neuronal ceroid lipofuscinosis are found to have mutations in Full Text of this Article
NEJM -- Sign In Genet Test 2000;4243248.CrossRefISIMedline; Zhong N, Moroziewicz DN, Ju W, et al. Heterogeneity of late-infantile neuronal ceroid lipofuscinosis. http://content.nejm.org/cgi/content/full/348/21/2159
Extractions: SIGN IN User Name Password Forgot your Password? Click here and we'll e-mail it to you. If you do not use cookies, sign in here. Remember my User Name and Password. Log in via Athens. PURCHASE THIS ARTICLE Purchase a single article and get immediate online access for just $10. If you're a subscriber but have not yet activated your full online access ACTIVATE YOUR SUBSCRIPTION Subscribers to NEJM are entitled to full access to all online content and features, including 20 FREE online CME exams. OR Receive full access to ALL current content and online features including Personal Archives, PDF article downloads, PDA access, E-mail alerts and 20 FREE online CME exams. OR Receive FREE online access to NEJM Original and Special Articles 6 months after publication and choose to receive the Table of Contents and notification of early release articles via e-mail.
Findis.org Infantile neuronal ceroid lipofuscinosis. Genes Palmitoyl protein thioesterase 1 (PPT1). Incidence in Finland 1/14 000. Number of Finnish Patients 150 http://www.findis.org/main.php?action=info&info=disease&disease_name=Infantile n
Extractions: This Article Abstract FREE Full Text (PDF) Alert me when this article is cited ... Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed ... Cited by other online articles Search for citing articles in: Oxford University Press Liina Lonka Susanna Ranta Anu Jalanko and Anna-Elina Lehesjoki Department of Medical Genetics, Haartman Institute, University of Helsinki, 00014 Helsinki, Finland and National Public Health Institute, Department of Human Molecular Genetics, Mannerheimintie 166, 00300 Helsinki, Finland Received 29 March 2000; Revised and Accepted 5 May 2000.
Extractions: Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed ... Request Permissions PubMed PubMed Citation Articles by Steinfeld, R. Robert Steinfeld Hans-Bertram Steinke Dirk Isbrandt and Department of Pediatrics, University Hospital Eppendorf, Hamburg, Germany and Centre of Molecular Neurobiology (ZMNH), University of Hamburg, Hamburg, Germany Received June 24, 2004;